Print Preview Area

Defining the aromatase inhibitor musculoskeletal syndrome: A prospective study
Arthritis Care & Research , 07/05/2012

Singer O et al. – Although some symptomatic subjects had new MRI abnormalities, RAMRIS scores did not significantly change. The incidence of Aromatase Inhibitors associated musculoskeletal syndrome is over 50% with most women developing symptoms by 8 weeks. The key finding in symptomatic women was focal tenosynovitis of the hands and feet, without evidence of autoimmune disease or systemic inflammation. Later stage cancer and poorer quality of life were predictive of symptom development.

Get reports via email to claim your reading activity at MDLinx as Category 2 CME (It takes less than a minute)

Stay current on the latest literature, research and clinical news
Get special communications and offers from MDLinx and our sponsors
Receive invitations to paid market research

View Samples and Register

Stay current - Media Tool

Newsletter

RSS

Facebook

Receive free subspecialty
"5-minute updates" via email

Send the E-mail Newsletter to a Colleague

♦ Subscribe to our free RSS feeds:
Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More ♦

♦ Follow Us on Twitter
Twitter is a rich source of instantly updated information. Join today and follow @MDLinx to start receiving tweets. Learn More ♦

♦ Follow Us on Facebook

Search the latest
Medical Student Jobs
@MDLinx Career Center
View the full listing of physician jobs

Enter your email address and your password will be sent to you.
Email:

E-mail:
Password:
	Remember me Forgot your password?

Defining the aromatase inhibitor musculoskeletal syndrome: A prospective study Arthritis Care & Research , 07/05/2012

Defining the aromatase inhibitor musculoskeletal syndrome: A prospective study
Arthritis Care & Research , 07/05/2012